Advanced Oncotherapy (AVO)

 

AVO Share PerformanceMore

52 week high91.850 09/01/17
52 week low9.525 19/07/17
52 week change -2.250 (-4.50%)
4 week volume9,427,018 20/11/17

Media for (AVO)

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Holding(s) in Company

RNS Number: 2803Z Advanced Oncotherapy PLC 13 December 2017 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Advanced Oncotherapy Plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of votin...

Hardman Res.: Distribution deal & capital increase

RNS Number: 9872Y Advanced Oncotherapy PLC 11 December 2017 Hardman Research: Distribution agreement and capital increase Distribution agreement and capital increase: AVO is focused on delivering a more affordable, novel, proton-based radiotherapy system, based on technology originally developed at the world-renowned CERN. Major milestones have be...

Advanced Oncotherapy - Distribution agreement and Equity Investments

Advanced Oncotherapy inks distribution deal

Advanced Oncotherapy has signed an exclusive distribution agreement to market and sell its LIGHT system across China, ...

Distribution agreement and Equity Investments

RNS Number: 6613Y Advanced Oncotherapy PLC 07 December 2017 ADVANCED ONCOTHERAPY PLC ("Advanced Oncotherapy" or the "Company") Exclusive distribution agreement for China and other geographies & new equity investments for a total consideration of 37 million Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton th...

AVO - Progress at Harley Street, timelapse

Advanced Oncotherapy operating losses widen

Advanced Oncotherapy's operating losses rose to 7.3m in the six months to the end of June - up from 5.9m last time. Revenu...

Half-year Report

RNS Number: 1735S Advanced Oncotherapy PLC 29 September 2017 ADVANCED ONCOTHERAPY PLC ("Advanced Oncotherapy" or the "Company") Half-year Report Advanced Oncotherapy (AIM: AVO), the developer of a next generation proton therapy system for cancer treatment, announces its unaudited results for the six months ended 30 June 2017 and po...

Fundamental DataMore

EPS-17.01
Dividend yield0 %

Latest discussion posts More

  • Great deal

    So there it is Great deal, by the looks of it. Fully financed for the long term, all looking on track. Directors buying more, and a partner to sell to the far east. Not ...
    7-Dec-2017
    fish lips
  • Nice tick-up

    Nice tick up today on smallish volume, hopefully means good news coming.
    4-Dec-2017
    fish lips
  • Re: Price rise

    Wow that's more than enough to cover the next few years and take them past live for Harley Street. I suppose it depends on how much they have to give away in equity, their ...
    6-Oct-2017
    fish lips

Users' HoldingsMore

Users who hold Advanced Oncotherapy also hold..

Codes & Symbols

ISINGB00BD6SX109
SymbolsAVO, LSE:AVO, AVO.L, AVO:LN, LON:AVO, XLON:AVO

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account